SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).

[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

Sar-[D-Phe8]-des-Arg9-Bradykinin acetate is a potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

[Sar1, Ile8]-Angiotensin II 3TFA ([Sar1, Ile8]-Angiotensin II 3TFA (37827-06-8(free base))) is a peptide that has multiple effects on vascular smooth muscle.

[Sar9]-Substance P acetate is one of NK-1 receptor agonist. The action of SP on progesterone metabolism was mimicked by the rNK1-specific agonist [Sar-9,Met(O2)11]-SP.

(Sar¹)-Angiotensin II acetate, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. It binds to brain membrane-rich particles, with a Kd of 2.7 nM. It can stimulate protein synthesis and cell growth in embryonic chick myocytes.

(Rac)-SAR131675 is an effective and specific VEGFR-3 inhibitor. It inhibited VEGFR-3 tyrosine kinase activity (IC50: 20 nmol/L) and VEGFR-3 autophosphorylation (IC50: 45 nmol/L) in HEK cells, respectively. SAR131675 is highly specific for VEGFR-3 versus 107 receptors, enzymes, ion channels, and 65 kinases. SAR131675 is a highly specific VEGFR-3-TK inhibitor with significant antitumoral and antimetastatic activities in vivo through inhibition of lymphangiogenesis and TAM invasion.

SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).

SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).

Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.

Sarilumab （SAR-153191）is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.

Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

[Sar9,Met(O2)11]-Substance P (NA) is an agonist of NK1 receptor.

The substitution with Sar at position 1 of angiotensin II resulted in a partial agonistic activity.

[Sar1, Ile8]-Angiotensin II(3TFA) is a peptide that has multiple effects on vascular smooth muscle.

SAR441255 is a potent unimolecular peptide that acts as a GLP-1/GIP/GCG receptor triagonist, demonstrating balanced activation across all three target receptors. It has shown positive acute glucoregulatory effects in diabetic obese monkeys [1].

SAR-114137 is an inhibitor of cysteine cathepsin with oral activity.

Edg-2 receptor inhibitor 1 (SAR-100842) is an Edg-2 receptor inhibitor extracted (IC50: <0.1 μM).

SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.

SAR247799 (S1P1 agonist 3) is an orally-active, selective G-protein-biased agonist for the sphingosine-1 phosphate receptor-1 (S1P1). It demonstrates EC50 values ranging from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 holds promise as a valuable tool for investigating endothelial protection, particularly in the context of type-2 diabetes and metabolic syndrome[4].

Potent P2Y12 antagonist (IC50 = 17 nM). Displays antiplatelet and antithrombotic activity in vivo. Orally available. Boldron et al (2014) N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J.Med.Chem. 57 7293 PMID:25075638

Biotin-sar-oh is a cleavable linker vital in ADC synthesis. Biotin-sar-oh joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

SAR7334 (TRCP6-IN-1) is a potent and specific inhibitor of TRPC6(IC50 of 7.9 nM).

SAR296968 is a novel selective NCX inhibitor, improving cardiac function and restoring sympathovagal balance in heart failure.

SAR-629 is an MGL inhibitor or 2-AG degradation inhibitor.

SAR502250 is a potent, selective, ATP-competitive, orally active, and brain-penetrant GSK3 inhibitor with a human GSK-3β IC50 value of 12 nM. It exhibits antidepressant-like activity and is being researched for potential application in Alzheimer’s disease (AD) treatment.

Fmoc-Sar-OH is a useful organic compound for research related to life sciences. The catalog number is T66699 and the CAS number is 77128-70-2.

SAR127303 is an effective covalent inhibitor of MAGL. SAR127303 behaves as a selective and competitive inhibitor of mouse and human MAGL.

SAR-104772 is a novel inhibitor of TAFIa (activated thrombin-activatable fibrinolysis inhibitor).

Laurylsarcosyltaurine is a surface active constituent of crab gastric juice.

SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is an inhibitor of PIK3C3/Vps34.

SAR-405 is a potent and selective PIK3C3/Vps34 inhibitor (IC50:1.2 nM; Kd:1.5 nM) that prevents autophagy and synergizes with MTOR inhibition in tumor cells. SAR405 treatment also inhibits autophagy induced either by starvation or by MTOR (mechanistic target of rapamycin) inhibition. Combining SAR405 with everolimus results in a significant synergy on the reduction of cell proliferation using renal tumor cells.

Pentasarcosyl angiotensin II is a synthetic analog of angiotensin II.

SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)

SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.

SAR407899 is Rho kinase inhibitor potently inhibits endothelin-1-induced constriction of renal resistance arteries.

SAR-7226 Hydrate, a SGLT1/2 inhibitor, is used potentially for the treatment of type 2 diabetes.

[Sar4] Substance P (4-11) is a Substance P agonist and an analog of the C-terminus fragment of Substance P, known as Substance P (4-11) [1].

(Sar1,Ile4,8)-Angiotensin II is a functionally selective agonist for the angiotensin II type 1 receptor (AT1R), enhancing insulin-stimulated signaling of the insulin receptor (IR) and glycogen synthesis. It boosts the insulin-induced phosphorylation of Akt and GSK3α/β [1].

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK 1 receptor selective agonist.

[MePhe8,Sar9] Substance P ([MePhe8-MeGly9] Substance P) is an analog of Substance P, a neuropeptide functioning both as a neurotransmitter and neuromodulator in the central nervous system (CNS).

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is an analogue of Substance P that acts on the neurokinin 1 receptor (NK1R) in rat brain, similarly to Substance P but with a significantly extended duration of action. This compound selectively enhances dopamine metabolism within the mesencephalon and midbrain cortex, increases motor activity, and facilitates the resumption of addictive agent-seeking behavior in rats [1] [2] [3].

SAR156497 is an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy with IC50 = 0.5 nM (Aurora A); 1 nM (Aurora B / incenp); 3 nM (Aurora C / incenp) respectively SAR156497 combines high in vitro potency with satisfactory metabolic stability and limited CYP 3A4 and PDE3 inhibition. In vitro, SAR156497 displayed high antiproliferative activity on a large panel of tumor cell lines without correlation with any particular genetic signature or Aurora kinases expression. It induced significant modulation of Aurora A and Aurora B biomarkers (p-Aurora A and pHH3, respectively) and cell polyploidy, as expected from Aurora A/B inhibitors.

[Glp5,Sar9] Substance P (5-11) is an analogue of Substance P [1] .

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody that targets the inducible costimulatory receptor (ICOS). This compound selectively depletes cells with high ICOS expression through antibody-dependent cellular cytotoxicity (ADCC), mediated by FcγRIIIa engagement. Meanwhile, it acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, via FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1].

Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody against programmed cell death receptor 1 (PD-1) and a checkpoint inhibitor that blocks PD-1/PD-L1 mediated T-cell inhibition and can be used in metastatic cancer and squamous cell skin cancer research.

Atuzabrutinib is a potent BTK (Bruton's tyrosine kinase) inhibitor.

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system and is a highly expressed protein in multiple myeloma. Isatuximab has antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, which can directly induce apoptosis in the absence of crosslinking. Isatuximab has an inhibitory effect on CD38 extracellular enzyme activity, which is associated with many cellular functions.

Itepekimab (REGN-3500) is a potent monoclonal antibody against IL-33.Itepekimab reduces airway inflammation and associated tissue damage in in vivo experiments and can be used to study asthma.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker. The mechanism of action of irbesartan is as an Angiotensin 2 Receptor Antagonist.